Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05665699 · ClinicalTrials.gov registry record · Phase 2
Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With Gout
A Phase 2 study of Gout, sponsored by InventisBio Co..
- Active
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 19
- Study locations
NCT05665699 is a Phase 2 study of Gout that is active but no longer recruiting, run by InventisBio Co.. The registered enrollment target is 80 participants, below the 8,886-participant average among 34 other Gout trials with a reported enrollment target (99% lower). The trial reports 19 study locations across 12 states.
The verdict
NCT05665699, a Phase 2 study of Gout, is active but no longer recruiting, sponsored by InventisBio Co..
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 19
- Study locations
Study Summary
D-0120 is being tested in combination with Allopurinol in adult subjects with Gout.
Conditions Studied
Interventions
- DRUG Allopurinol
- DRUG D-0120
Study Locations (19)
North Carolina
- Study Center - Hickory
- Study Center - Rocky Mount
- Study Center - Salisbury
- Study Center - Wilmington
- Study Center - Winston-Salem
Tennessee
- Study Center - Bristol
- Site Center - Hendersonville
- Study Center - Knoxville
Texas
- Site Center - Fort Worth
- Site Center - The Woodlands
Alabama
- Study Center - Birmingham
Florida
- Site Center - Plantation
Illinois
- Study Center - Evergreen Park
Indiana
- Study Center - Brownsburg
Kentucky
- Site Center - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2023-04-17 |
| Est. Completion | 2025-12-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05665699
The ClinicalTrials.gov registry entry for NCT05665699 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 8,886-participant average among 34 other Gout trials with a reported enrollment target (99% lower). The listed sponsor is InventisBio Co., which has 11 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Gout appearing as the primary indexed condition, and to 2 interventions - of which Allopurinol is the first listed.
NCT05665699 reports 19 study locations spanning 12 distinct geographic areas - top geographies include North Carolina, Tennessee, Texas.
Frequently Asked Questions
What is clinical trial NCT05665699 about?
NCT05665699 is a clinical study titled "Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With Gout". D-0120 is being tested in combination with Allopurinol in adult subjects with Gout.
What is the current status of trial NCT05665699?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2023-04-17. Estimated completion is 2025-12-30.
What conditions does trial NCT05665699 study?
This clinical trial studies the following conditions: Gout.
What interventions are being tested in trial NCT05665699?
The interventions under investigation include: Allopurinol (DRUG), D-0120 (DRUG).
Who is sponsoring clinical trial NCT05665699?
This trial is sponsored by InventisBio Co., which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05665699 being conducted?
This trial has 19 study locations across Alabama, Florida, Illinois, Indiana, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gout
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE)
RECRUITING · Phase 2
-
Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients
RECRUITING · Phase 2
-
Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare
RECRUITING · Phase 2
-
Dose Finding Study to Evaluate Safety and Efficacy of 3 Dosages of SAP 001.
ACTIVE NOT RECRUITING · Phase 2
-
A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency
COMPLETED · Phase 2
-
Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With Gout
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.